Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...

Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by ...

Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...

As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, ...

Despite executing "perfectly," Octagon confronted a “scientific no-go,” CEO Isaac Stoner said in his LinkedIn post announcing ...